<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00695591</url>
  </required_header>
  <id_info>
    <org_study_id>LS01</org_study_id>
    <nct_id>NCT00695591</nct_id>
  </id_info>
  <brief_title>Home Sleep Testing in Neuromuscular Disease Patients</brief_title>
  <acronym>HSTNMD</acronym>
  <official_title>Home Sleep Testing in Neuromuscular Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Landon Pediatric Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Landon Pediatric Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lay Summary Patients with severe neuromuscular develop hypoventilation, which leads to
      elevated carbon dioxide levels. Measuring only oxygen saturation levels with pulse oximetry
      may be inadequate. End tidal carbon dioxide levels or arterial blood gases should be measured
      periodically, depending on the clinical condition of the patient. A thorough review of
      systems will help define any problems. Patients who are hypoventilating often have elevated
      carbon dioxide levels at night and complain of a morning headache, restlessness or
      nightmares, and poor quality sleep. This may cause daytime sleepiness. Insufficient
      respiration with hypoxia may occur later, especially if the lung is damaged by chronic
      aspiration.

      We propose to evaluate the use of the Nonin LifeSense monitor in home evaluation of
      respiration, oxygen level, heart rate, and carbon dioxide level and to develop interpretation
      of the results that will lead to appropriate interventions for apnea, and insufficient
      respiration.

      Relevance to MDA Fewer than one per cent of the Muscular Dystrophy Association have
      pulmonologists as co-directors.Late referral of progressive restrictive lung disease leads to
      invasive support of respiratory failure. Early initiation of non invasive ventilation
      techniques requires patience on the part of the caregiver and exploration of mask interfaces
      and ventilation techniques. In addition, the development of new therapies, currently
      manifested through enhanced diagnostic accuracy, will require new signal for initiation and
      in the assessment of success or failure.

      Aims Aim 1. To assess the utility of a small portable device (LifeSense Monitor Nonin Medical
      Inc. Plymouth Minnesota) with extended recording capabilty to provide accurate diagnosis of
      hypoventilation.

      Aim 2. To provide an easily interpretable report defining sleep hypoxemia, hypercapnea, and
      apnea.

      Aim 3. To promote early evaluation and treatment of the respiratory problems in centers that
      do not have pumonologists as these are essential to prognosis, whether of survival or of
      quality of life, in neuromuscular diseases.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>1. End tidal CO2 catheter is tolerated for six hours or more</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Interpretable data are captured for oximetry, heart rate, and end-tidal CO2</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. An interpretive report is generated that will guide the non-pulmonary physician in potential interventions</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Patients and parents are able to apply the monitors at home and a six hour data set is collected</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">9</enrollment>
  <condition>Neuromuscular Disease</condition>
  <arm_group>
    <arm_group_label>1SevereRLD,NMD</arm_group_label>
    <description>Patients with FEV1&lt;40%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2VerySevereRLD,NMD</arm_group_label>
    <description>FEV1&lt;30%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3NINV</arm_group_label>
    <description>FEV1&lt;25%,on non invasive ventilation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ModerateRLD,NMD</arm_group_label>
    <description>Patients with FEV1 40-50% of predicted</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation for Nocturnal non invasive ventilation</intervention_name>
    <description>Patients will be referred for evaluation for NNIV is indicated in patients with diurnal Pa,CO2 &gt;6.0 Pa; and 2) nocturnal Sa,O2 &lt;88% for 5 consecutive min. End tidal CO2 representing equivalent values will be referred for NNIV</description>
    <arm_group_label>1SevereRLD,NMD</arm_group_label>
    <arm_group_label>2VerySevereRLD,NMD</arm_group_label>
    <arm_group_label>3NINV</arm_group_label>
    <arm_group_label>ModerateRLD,NMD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study Population Description Patients from the Neuromuscular Disease Clinic at Ventura
        County Medical Center

        Non-Probability Sample: invitation to volunteer

        Neuromuscular Disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of neuromuscular disease

          -  Must have home caregivers

        Exclusion Criteria:

          -  No home caregiver
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Landon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Landon Pediatric Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pediatric Diagnostic Center</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pediatrics.aappublications.org/content/123/Supplement_4/S250.full.pdf</url>
    <description>Novel Methods of Ambulatory Physiologic Monitoring in Patients With Neuromuscular Disease</description>
  </link>
  <reference>
    <citation>Shneerson JM, Simonds AK. Noninvasive ventilation for chest wall and neuromuscular disorders. Eur Respir J. 2002 Aug;20(2):480-7. Review.</citation>
    <PMID>12212984</PMID>
  </reference>
  <reference>
    <citation>Kumar SP, Sword D, Petty RK, Banham SW, Patel KR. Assessment of sleep studies in myotonic dystrophy. Chron Respir Dis. 2007;4(1):15-8.</citation>
    <PMID>17416148</PMID>
  </reference>
  <reference>
    <citation>Kirk VG, Flemons WW, Adams C, Rimmer KP, Montgomery MD. Sleep-disordered breathing in Duchenne muscular dystrophy: a preliminary study of the role of portable monitoring. Pediatr Pulmonol. 2000 Feb;29(2):135-40.</citation>
    <PMID>10639204</PMID>
  </reference>
  <reference>
    <citation>Birnkrant DJ, Panitch HB, Benditt JO, Boitano LJ, Carter ER, Cwik VA, Finder JD, Iannaccone ST, Jacobson LE, Kohn GL, Motoyama EK, Moxley RT, Schroth MK, Sharma GD, Sussman MD. American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation. Chest. 2007 Dec;132(6):1977-86.</citation>
    <PMID>18079231</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2008</study_first_submitted>
  <study_first_submitted_qc>June 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2008</study_first_posted>
  <last_update_submitted>August 12, 2014</last_update_submitted>
  <last_update_submitted_qc>August 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Home sleep testing neuromuscular disease</keyword>
  <keyword>Neuromuscular disease patients with FEV1&lt;50% of predicted</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuromuscular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

